Get the Stockscreener App
0.89
60.53%
0.3356
After Hours:
.92
0.03
+3.37%
Vor Biopharma Inc stock is traded at $0.89, with a volume of 281.34M.
It is up +60.53% in the last 24 hours and up +403.96% over the past month.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
See More
Previous Close:
$0.5544
Open:
$1
24h Volume:
281.34M
Relative Volume:
139.65
Market Cap:
$28.68M
Revenue:
-
Net Income/Loss:
$-112.46M
P/E Ratio:
-0.5427
EPS:
-1.64
Net Cash Flow:
$-99.89M
1W Performance:
+315.89%
1M Performance:
+403.96%
6M Performance:
+6.21%
1Y Performance:
-22.61%
1-Day Range:
$0.712
$1.26
1-Week Range:
$0.2145
$1.26
52-Week Range:
$0.1311
$1.80
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
100 CAMBRIDGEPARK DRIVE, CAMBRIDGE
Compare VOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
0.89 | 28.68M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
Short Interest in Vor Biopharma Inc. (NYSE:VOR) Increases By 51.8% - Defense World
Vor Biopharma Inc (VOR) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Market Insights: Triller Group Inc (ILLR)’s Notable Gain of 1.91, Closing at 0.69 - DWinneX
Vor Biopharma Inc (VOR) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Data-Based Insights About Vor Biopharma Inc (VOR) - Stocksregister
Vor Biopharma Inc. (NYSE:VOR) Given Average Recommendation of “Hold” by Analysts - Defense World
Northern Trust Corp Acquires 44,252 Shares of Vor Biopharma Inc. (NYSE:VOR) - Defense World
Cambridge biotech company researching blood cancers to close, lay off 155 - Yahoo Finance
Vor Biopharma Inc (NASDAQ: VOR) Stock Forecast: Could Pass $6 In A Year - Stocksregister
Vor Biopharma’s SWOT analysis: biotech firm halts programs, explores options By Investing.com - Investing.com South Africa
Vor Biopharma’s SWOT analysis: biotech firm halts programs, explores options - Investing.com
Vor Biopharma Approves Share Increase at Annual Meeting - TipRanks
Vor Biopharma Appoints Robert Ang as CFO - TipRanks
What Did We Note About Insider Trading At Vor Biopharma Inc (NASDAQ: VOR)? - Stocksregister
FMR LLC's Strategic Acquisition of Vor Biopharma Inc Shares - GuruFocus
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Hold” by Analysts - Defense World
Vor Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Vor Biopharma Inc. SEC 10-Q Report - TradingView
Research Analysts’ Recent Ratings Updates for Vor Biopharma (VOR) - Defense World
Vor Biopharma (NYSE:VOR) Cut to “Hold” at Jones Trading - Defense World
HC Wainwright Reaffirms Neutral Rating for Vor Biopharma (NYSE:VOR) - Defense World
Vor Biopharma’s (VOR) Neutral Rating Reiterated at Wedbush - Defense World
Vor Biopharma (VOR) Downgraded by HC Wainwright & Co. from Buy t - GuruFocus
VorBio (VOR) Downgraded Amid Strategic Review Announcement | VOR Stock News - GuruFocus
Vor Biopharma (VOR) Drops Sharply After Downgrades and Operational Halt - GuruFocus
Stifel cuts Vor Biopharma stock rating amid clinical and financial concerns By Investing.com - Investing.com South Africa
VorBio (VOR) Downgraded as Company Explores Strategic Alternativ - GuruFocus
Stifel cuts Vor Biopharma stock rating amid clinical and financial concerns - Investing.com Canada
Vor Biopharma stock draws downgrades (VOR:NASDAQ) - Seeking Alpha
Layoff Tracker: Shape, Vor Cut Workforces - BioSpace
Vor Biopharma (VOR) Downgraded by JMP Securities | VOR Stock New - GuruFocus
Baird Downgrades Vor Biopharma to Neutral From Outperform - marketscreener.com
This International Paper Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - Benzinga
Vor Biopharma (VOR) Downgraded by HC Wainwright & Co. from Buy to Neutral | VOR Stock News - GuruFocus
Closing Bell Recap: Vor Biopharma Inc (VOR) Ends at 0.16, Reflecting a -70.12 Downturn - DWinneX
VorBio (VOR) Downgraded as Company Shifts Strategy | VOR Stock News - GuruFocus
VorBio (VOR) Downgraded as Company Explores Strategic Alternatives | VOR Stock News - GuruFocus
Stifel Downgrades Vor Biopharma, Inc. (VOR) to Hold - StreetInsider
Baird cuts Vor Biopharma stock rating, slashes target to $0.25 By Investing.com - Investing.com Nigeria
Baird cuts Vor Biopharma stock rating, slashes target to $0.25 - Investing.com
Jones Trading cuts Vor Biopharma stock rating to Hold By Investing.com - Investing.com Nigeria
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga
Jones Trading cuts Vor Biopharma stock rating to Hold - Investing.com
Vor Biopharma stock plummets on operation wind-down - Investing.com Australia
Vor Biopharma stock plummets on operation wind-down By Investing.com - Investing.com Canada
Vor Biopharma Terminates CFO Han Choi - marketscreener.com
Vor Bio Announces Exploration Of Strategic Alternatives To Maximize Shareholder Value - marketscreener.com
Wedbush Downgrades Vor Biopharma to Neutral From Outperform, Adjusts Price Target to $0.40 From $7 - marketscreener.com
Vor Bio (VOR) Downgraded to Hold as Strategic Alternatives Explored | VOR Stock News - GuruFocus
Jones Trading Downgrades Vor Biopharma, Inc. (VOR) to Hold - StreetInsider
Dow Jumps Over 200 Points; US Initial Jobless Claims Fall - Benzinga
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):